Clinical Trials Browser

Phase 1/2 × orelabrutinib × Lymphoid × Clear all

NCT04014205 2023-04-18

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Phase 1/2 Unknown

Part 1：r/r B-cell Malignancies

NCT05021770 2021-08-26

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

Phase 1/2 Unknown

Lymphoma, Non-Hodgkin